Oxford – Brainomix Ltd, a company developing imaging biomarkers for neurological and cerebrovascular disorders, announced today that it has completed a £1.5 million investment round. This will enable Brainomix to further commercialize its proprietary medical imaging software, e-ASPECTS, and expand its market penetration in Europe, Latin America and the United States. The round was led by Chimera Partners and Parkwalk Advisors with all existing investors participating in the investment round.

Fast and accurate interpretation of brain CT scans is essential for selecting stroke patients for life saving treatment. Existing manual processes are subjective, costly and limited by the lack of available expert clinicians. With e-ASPECTS, Brainomix provides physicians with a clinical support tool that is designed to improve stroke treatment outcomes at much lower overall cost. In particular, e-ASPECTS automatically identifies and quantifies signs of early stroke damage on brain CT scans giving hospitals and their physicians access to reliable and standardised diagnoses for their patients quickly and efficiently.

Chimera Partners’ Mark Jaffray said: “We are delighted to back a fantastic team focused on delivering technology that significantly improves treatment decisions for stroke patients at lower cost in our key markets and with our key partners around the world”.

Brainomix CEO Dr Michalis Papadakis said: “In a short time, we have built a software solution that empowers physicians around the world to treat stroke in a more efficient, fast and consistent way. In particular, e-ASPECTS supports the clinical decisions of physicians, helping them to interpret the scans of stroke victims to the level of an expert in the field. We are very pleased to be supported by our investors, in a common effort to see Brainomix penetrate even more markets worldwide. Our aim is to become the world leader in imaging biomarkers for neurological and cerebrovascular disorders”.